Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 15 for:    psvt

Study on Left Atrial Function of Paroxysmal Supraventricular Tachycardia After Radiofrequency Ablation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03348436
Recruitment Status : Completed
First Posted : November 20, 2017
Last Update Posted : March 18, 2020
Sponsor:
Information provided by (Responsible Party):
Ruiqin xie, The Second Hospital of Hebei Medical University

Brief Summary:
This study to investigate the effects of RF ablation on left atrial systolic function in patients with atrioventricular nodal reentrant tachycardia (AVNRT) and atrioventricular tachycardia (AVRT).

Condition or disease Intervention/treatment Phase
Paroxysmal Supraventricular Tachycardia Procedure: radiofrequency ablation Not Applicable

Detailed Description:
A total of 100 patients with persistent,in whom successful RF ablation of slow pathway or accessory pathway was performed. Patients with atrial fibrillation, structural heart disease, ventricular arrhythmias, impaired left ventricular systolic function or on antiarrhythmics were excluded. All the patients had echocardiographic study before ablation 、1 day and 1 months after ablation. Left atrial systolic function was assessed using atrial ejection force (AEF) according to Manning's formula (AEF = 0.5 x ρ x MA x A(2), r: blood density = 1.06 g/cm(3), MA: mitral orifice area [cm(2)], A: A wave velocity). The following left atrial dimensions were assessed: antero-posterior (LA-AP), infero-superior (LA-IS, long axis), medio-lateral (LA-ML, short axis). The correlations between AEF and electrophysiological parameters were analysed (VA - ventriculo-atrial conduction, VA/CL - tachycardia cycle length).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: A total of 100 patients with persistent,in whom successful RF ablation of slow pathway or accessory pathway was performed. Patients with atrial fibrillation, structural heart disease, ventricular arrhythmias, impaired left ventricular systolic function or on antiarrhythmics were excluded. All the patients had echocardiographic study before ablation 、1 day and 1 months after ablation.
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Study on Left Atrial Function of Paroxysmal Supraventricular Tachycardia After Radiofrequency Ablation
Actual Study Start Date : January 1, 2017
Actual Primary Completion Date : March 1, 2020
Actual Study Completion Date : March 1, 2020

Arm Intervention/treatment
Experimental: patients with atrioventricular nodal reentrant tachycardia
radiofrequency catheter ablation therapy
Procedure: radiofrequency ablation
Experimental: patients with atrioventricular tachycardia
radiofrequency catheter ablation therapy
Procedure: radiofrequency ablation



Primary Outcome Measures :
  1. Left Atrial Function of postoperative radiofrequency ablation. [ Time Frame: 1 month ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   14 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients with paroxysmal supraventricular tachycardia,includes atrioventricular reentrant tachycardia and atrioventricular nodal reentrant tachycardia, Age is >14 years

Exclusion Criteria:

Atrial fibrillation, Atrial tachycardia, Structural heart disease, Ventricular arrhythmias, Patients with impaired left ventricular systolic function or on antiarrhythmics


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03348436


Locations
Layout table for location information
China, Hebei
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China, 050000
Sponsors and Collaborators
Ruiqin xie
Layout table for additonal information
Responsible Party: Ruiqin xie, director of cardiology department, The Second Hospital of Hebei Medical University
ClinicalTrials.gov Identifier: NCT03348436    
Other Study ID Numbers: xierqdoctorSVT
First Posted: November 20, 2017    Key Record Dates
Last Update Posted: March 18, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ruiqin xie, The Second Hospital of Hebei Medical University:
paroxysmal supraventricular tachycardia
Left Atrial Function
Additional relevant MeSH terms:
Layout table for MeSH terms
Tachycardia
Tachycardia, Supraventricular
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Cardiac Conduction System Disease
Pathologic Processes